6533b837fe1ef96bd12a286e
RESEARCH PRODUCT
Incretin-based therapies in 2021 – Current status and perspectives for the future
Michael A. NauckChristos S. MantzorosManfredi Rizzosubject
medicine.medical_specialtyDipeptidyl-Peptidase IV Inhibitorsbusiness.industryEndocrinology Diabetes and MetabolismMEDLINEIncretinDiabetes Mellitus Type 2 Dipeptidyl-Peptidase IV Inhibitors Glucagon-Like Peptide-1 Receptor Humans Hypoglycemic Agents IncretinsIncretinsGlucagon-Like Peptide-1 ReceptorArticleEndocrinologyDiabetes Mellitus Type 2Internal medicinemedicineHumansHypoglycemic AgentsCurrent (fluid)Intensive care medicinebusinessyear | journal | country | edition | language |
---|---|---|---|---|
2021-09-01 |